“maximum strength” OTC claim plausibly misleading where prescription strength was stronger

Acosta-Aguayo v. Walgreen Co., No. 22-cv-00177, 2023 WL
2333300 (N.D. Ill. Mar. 2, 2023)

Plaintiffs alleged that three of Walgreens’ pain-relieving
products mislead consumers because the products’ front labels state that they
are “Maximum Strength” lidocaine products, but stronger prescription products
are available. This was plausible on a motion to dismiss.

Plaintiffs alleged that consumers consider dose strength an
important factor when purchasing pain-relieving products. But competitors allegedly
offer similar prescription patches that contain 5% lidocaine and an
over-the-counter cream product that contains 5% lidocaine.

The court also found that the plaintiffs could represent
purchasers of a different patch product, which was substantially similar “in
the colors of the packages and text, the images displayed, the text style and
text descriptions in the bullet points, and the shape and size of the
packaging.” But the challenged cream wasn’t substantially similar.

Walgreens argued that “[n]o reasonable consumer purchasing
one of the Products would read ‘Maximum Strength’ on the labels to literally
mean that the Products contain the maximum amount of lidocaine that a person
could ever obtain anywhere.” But, “[w]hile a reasonable consumer likely
understands the difference between over the counter and prescription drugs, a
reasonable consumer would not necessarily understand the ‘Maximum Strength’ on
the Product’s label to exclude comparable prescription medication…. Reading the
phrase ‘Maximum Strength’ to mean the maximum strength of lidocaine available
generally is not an “unreasonable or fanciful interpretation[ ]’ of the
Product’s label.”

Walgreens argued that the claim was implausible because 4%
is the maximum concentration permitted by the FDA in non-prescription external
analgesics. But it didn’t argue that a reasonable consumer would know this, and
the label could still be misleading. A similar case,  Scilex Pharms. Inc. v. Sanofi-Aventis U.S.
LLC, 552 F. Supp. 3d 901 (N.D. Cal. 2021), concluded that the plaintiff stated
a claim under the UCL or FAL by alleging that defendants’ advertising and
marketing is likely to deceive a reasonable consumer to believe, among other
things, that Defendants’ patches offer ‘the maximum amount of lidocaine
available in patch form.’ ” Factual development was required.

Claims for beach of express and implied warranties ere
dismissed for failure to give pre-suit notice, as was common-law fraud for
conclusory allegations about knowledge and intent; defendants didn’t have a
fiduciary duty to disclose. Unjust enrichment did survive at this stage, as did
claims on behalf of a multi-state class.

Injunctive relief claims were dismissed for want of
standing, which also got rid of the state UDTPA claims, and because plaintiffs failed
to allege that they lacked an adequate remedy at law, the court dismissed their
claims for restitution and disgorgement.


from Blogger http://tushnet.blogspot.com/2023/03/maximum-strength-otc-claim-plausibly.html

This entry was posted in Uncategorized and tagged , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s